Given that mast cell MRGPRX2 plays a pivotal role in mediating pseudo-allergic reactions to several FDA-approved drugs and chronic inflammation associated with asthma, urticaria and rosacea, our studies provide a strong rationale for testing osthole as a novel treatment option for these conditions. This evidence concerns the gene MRGPRX2 and asthma.